Skip to main content
Premium Trial:

Request an Annual Quote

Iconix, Schering-Plough Research Institute in Toxicogenomics Partnership

NEW YORK, Jan. 30-Iconix Pharmaceuticals and the Schering-Plough Research Institute will collaborate in toxicogenomic marker research, Iconix said today.

 

The partners will look for new biomarkers related to toxic responses in the liver, kidney, and heart that may be used in early stage drug development.

 

Intellectual property details and financial specifics of this partnership were not available.

 

The Schering-Plough Research Institute is the pharmaceutical R&D division of Schering-Plough.

 

Iconix is a privately held company focusing on developing chemogenomics capabilities. It is based in Mountain View, Calif.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.